DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Procardia (Nifedipine) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

PROCARDIA SUMMARY

PROCARDIA®
(nifedipine)
CAPSULES
For Oral Use

PROCARDIA® (nifedipine) is an antianginal drug belonging to a class of pharmacological agents, the calcium channel blockers.

I. Vasospastic Angina

PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers.

    (Classical Effort-Associated Angina)

PROCARDIA is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.

In chronic stable angina (effort-associated angina) PROCARDIA has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete.

Controlled studies in small numbers of patients suggest concomitant use of PROCARDIA and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS.)


See all Procardia indications & dosage >>

PROCARDIA NEWS HIGHLIGHTS

Media Articles Related to Procardia (Nifedipine)

After Premature Labor, Maintenance Tocolysis No Help for Baby or Mother
Source: MedPage Today OB/Gyn [2008.11.26]

more >>

Published Studies Related to Procardia (Nifedipine)

Nifedipine improves endothelial function: role of endothelial progenitor cells. [2008.09]

Nifedipine as a Uterine Relaxant for External Cephalic Version: A Randomized Controlled Trial. [2008.08]

Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. [2008.07]

Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. [2008.05]

Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. [2008.05]

more >>

Clinical Trials Related to Procardia (Nifedipine)

Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension [Completed]

Losartan Therapy in Pulmonary Hypertension [Completed]

Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery [Not yet recruiting]

Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis [Completed]

Oral Nifedipine to Treat Iron Overload [Recruiting]

more >>

Page last updated: 2008-11-26

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008